How should an elderly male on anticoagulant therapy with chronic epistaxis that has stopped in the emergency department be managed?

Management of Elderly Male on Anticoagulation with Resolved Epistaxis in the Emergency Department

Do not withhold or reverse anticoagulation for this patient unless the bleeding was life-threatening, and proceed with first-line local control measures before considering any medication changes. 1

Immediate Management Approach

Since the bleeding has already stopped in the ER, your priority is to:

1. Continue Anticoagulation

• Do not routinely discontinue blood thinners 1
• The 2020 AAO-HNS guidelines explicitly recommend against withholding anticoagulants or administering reversal agents prior to attempting first-line interventions
• Stopping anticoagulation increases thrombotic risk (stroke, MI, valve thrombosis) which often outweighs the bleeding risk 1
• Studies show epistaxis can be successfully managed with local measures alone in anticoagulated patients 2, 3

2. Identify and Treat the Bleeding Source

Even though bleeding has stopped, you should:

Perform nasal endoscopy to identify the bleeding site (successful in 87-93% of cases) 1

• Anterior bleeding: typically Kiesselbach's plexus on septum
• Posterior bleeding: septum (70%) or lateral nasal wall (24%)

Apply appropriate local treatment 1:

• Topical vasoconstrictors: Oxymetazoline or phenylephrine (controls 65-75% of cases)
• Nasal cautery: Silver nitrate or bipolar cautery with local anesthesia (80% success rate) 4
• Moisturizing agents: After bleeding stops, use nasal saline/emollients to prevent recurrence

3. Risk Stratification for Anticoagulation Management

Only consider temporary anticoagulation adjustment if:

• Bleeding was truly life-threatening (massive hemorrhage, hemodynamic instability)
• Patient has high thrombotic risk requiring careful balancing 5:
  • Mechanical heart valve (especially mitral)
  • Recent stroke/TIA (within 3 months)
  • CHA₂DS₂-VASc ≥4
  • Recent VTE (within 3 months)
  • Active cancer with VTE history

If anticoagulation must be temporarily held in high-risk patients 5:

• Use unfractionated heparin IV (short half-life, reversible with protamine)
• Or prophylactic-dose LMWH subcutaneously
• Resume therapeutic anticoagulation as soon as hemostasis is secure

Discharge Planning

Before Discharge:

• Ensure hemostasis is achieved with local measures
• Check blood pressure - hypertension is a major risk factor for recurrence 6, 7, 8
• Review INR if on warfarin - supratherapeutic levels may warrant dose adjustment (not complete cessation)
• Consider switching from warfarin to DOAC if INR was supratherapeutic 5

Patient Instructions:

• Nasal care: Use saline spray and humidification regularly 1
• Avoid trauma: No nose picking, rubbing, or forceful blowing
• Apply emollients: Petroleum jelly or prescribed ointments to prevent crusting
• Blood pressure control: Critical for preventing recurrence 6, 8

Follow-up:

• ENT referral for recurrent epistaxis or if posterior source identified
• Primary care follow-up within 1-2 weeks to reassess anticoagulation need and optimize cardiovascular management
• Return precautions: Rebleeding, signs of anemia, hemodynamic instability

Key Pitfalls to Avoid

⚠️ Do not routinely reverse anticoagulation - this exposes patients to thrombotic complications (stroke, MI) that often have worse outcomes than epistaxis 1, 2

⚠️ Do not use blood products (FFP, platelets, PCC) unless life-threatening - these carry significant risks and are rarely needed 1

⚠️ Do not discharge without identifying the bleeding site - nasal endoscopy allows targeted treatment and reduces recurrence 1

⚠️ Do not ignore hypertension - uncontrolled BP is the most common modifiable risk factor for recurrent epistaxis 6, 7, 8

Evidence Quality Note

The 2020 AAO-HNS guideline 1 provides Grade C evidence (observational studies and expert opinion) but with high confidence that the benefit of continuing anticoagulation outweighs harm. This is supported by multiple retrospective studies showing successful management without routine anticoagulation reversal 2, 3. The ACC 2020 consensus 5 reinforces that only patients with both life-threatening bleeding AND high thrombotic risk require bridging strategies.